Invent Here, Make Here Act of 2024

CHIPS and Science Act (Public Law 117-167) implementation; S. 4585 and H.R. 8826, Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S. 1956, Invent Here, Make Here Act of 2024, S. 2228, Building Chips in America Act Issues related to Bayh-Dole and domestic manufacturing, federal incentives for semiconductor manufacturing, CHIPS Act funding and implementation, artificial intelligence chips, and supply chain resiliency

Client expense: $1,120,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

CHIPS and Science Act (Public Law 117-167); S. 4585 and H.R. 8826, Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S. 1956, Invent Here, Make Here Act of 2024 Issues related to the implementation of the National Semiconductor Technology Center, federal incentives for semiconductor research and development and manufacturing, CHIPS Act funding and implementation, semiconductor security, and artificial intelligence

Client expense: $1,120,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) H.R.9221 - RESTORE Patent Rights Act of 2024 S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law S.4840 - RESTORE Patent Rights Act of 2024 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $41,265 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Department of Energy proposals regarding domestic manufacturing regulations White House Executive Order on Federal Research and Development in Support of Domestic Manufacturing and U.S. Jobs -- particularly in relation to waivers of domestic manufacturing NIST Request for Information (Docket No. 230831-0207)regarding Draft Interagency Guidance Framework for Considering the Exercise of March-in Rights (all) S. 1956 -- Invent Here, Make Here Act -- related to requiring that inventions developed using federal funds be manufactured in the United States -- sections related to new requirements under the Bayh-Dole Act and creation of database of American manufacturers House companion bill to S. 1956 -- same issues

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act) Ensure free-market-based licensing terms and royalty rate settings of standard-essential patents (SEPs) Codification of 2019 Joint Policy Statement on Remedies for Standards-Essential Patents

Client expense: Not reported · Firm income: $7,600

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2023 S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Client expense: $1,540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 . S. 1250 Drug-price Transparency for Consumers Act S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to patent thickets/product hopping Issues related to obviousness/ double patenting S.2140 Patent Eligibility Restoration Act of 2023 S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. H.R. 3535 Advancing Americas Interests Act H.R. 5475 Prohibiting Adversarial Patents Act of 2023 S.3385/HR 8333-- BIOSECURE Act BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities Issues related to FDA/PTO coordination S.2780 Medication Affordability and Patent Integrity Act Issues related to skinny labeling S. 3583/HR 6986 To Address Patent Thickets S. 1956 Invent It Here, Make It Here Act

Client expense: $2,770,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CHIPS and Science Act (Public Law 117-167); S. 4585 and H.R. 8826, Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S. 1956, Invent Here, Make Here Act of 2024 Issues related to the implementation of the National Semiconductor Technology Center, federal incentives for semiconductor research and development and manufacturing, CHIPS Act funding and implementation, semiconductor security, artificial intelligence, quantum computing, National Quantum Initiative

Client expense: $1,600,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

CHIPS and Science Act (Public Law 117-167) implementation; S. 4585 and H.R. 8826, Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S. 1956, Invent Here, Make Here Act of 2024, S. 2228, Building Chips in America Act Issues related to Bayh-Dole and domestic manufacturing, federal incentives for semiconductor manufacturing, CHIPS Act funding and implementation, and supply chain resiliency

Client expense: $1,600,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---S.1956 Invent Here, Make Here Act of 2023 (Baldwin) ---Bayh-Dole Act ---March-In Rights ---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights ---Reasonable Pricing Clause Compulsory Licensing Data Privacy Issues ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---H.R. 8818: American Privacy Rights Act of 2024 ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain Diversity in Patenting ---S.2566: Inventor Diversity for Economic Advancement (IDEA) Act Drug Patenting ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---S. 2780 - Medication Affordability and Patient Integrity Act ---S.3583/H.R.6986: A bill to address patent thickets ---H.R.5475 Prohibiting Adversarial Patents Act of 2023 (Fitzgerald - WI) ---H.R. 6275 Protecting Consumer Access to Generic Drugs Act ---FTC Orange Book Delisting Initiative ---Orange Book Listing ---PTO Proposed Rules on Terminal Disclaimer Practice ---Restrictions on Intellectual Property Rights Foreign Drug Data Protection Law ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain Intellectual Property Enforcement ---China ---TRIPS Waiver Patent Reform ---H.R.4575: Prohibiting Adversarial Patents Act (PAPA) ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.2140: Patent Eligibility Restoration Act (PERA) ---S.2220/H.R.4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act ---Patent Litigation Reform ---The USPTO Request for Comments: Experimental Use Defense 89 Fed.Reg 53963 Patenting of Biological Inventions ---S.2140: Patent Eligibility Restoration Act (PERA) ---Section 101 Modernization World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge World Trade Organization (WTO) ---TRIPS Waiver

Client expense: $1,680,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office

General provisions related to science and engineering research at NSF, DOE, DOD, NASA, NIH, and IES in FY 2025 H.R. 9026 /S. 4795, the FY 2025 Commerce-Justice-Science Appropriations bill - provisions related to funding for NSF and NASA (including Science, Space Technology, STEM Education, and lunar gravitational waves) H.R. 8774 /S. 4921, the FY 2025 Defense Appropriations bill - provisions related to funding for basic and applied research (6.1-6.3) including Defense-Wide basic research initiatives and funding at DARPA; provisions related to research programs within Army Futures Command; provisions related to dependable AI for national security H.R. 8997 /S. 4927, the FY 2025 Energy-Water Appropriations bill - provisions related to funding for the Dept. of Energys Office of Science, ARPA-E, and language related to independent review and applied research for cleanup decision-making H.R. 9029/S. 4942, the FY 2025 Labor-HHS-Education Appropriations Act - provisions related to funding for the National Institutes of Health, and the Institute of Education Sciences (and National Center for Special Education Research); provisions related to F&A cost reimbursements H.R. 8070/S. 4368, the FY 2025 National Defense Authorization Act - provisions related to defense S&T basic and applied research (6.1-6.3); research security; research programs within Army Futures Command; dependable AI for national security; potential amendments related to Sec. 117 foreign gift reporting for universities and Workforce Pell Act S. 4667, the Risky Research Review Act - provisions related to creation of a Life Sciences Research Security Board to oversee certain high risk research S. 2220, the PREVAIL Act - provisions related to reforms to the PTAB H.R. 8958, the NASA Reauthorization Act - provisions related to Science, Space Technology, Aeronautics, and STEM Education H.R. xxxx/S. xxxx, the American Privacy Rights Act - provisions related to inclusion of universities as covered entities; impact on education research H.R. 1157, the Countering the PRC Malign Influence Fund Authorization Act of 2023 - provisions that authorize funding for a Countering the PRC Malign Influence Fund H.R. 7686 - provisions that would amend the Research and Development, Competition, and Innovation Act to clarify the definition of foreign country for purposes of malign foreign talent recruitment restriction H.R. 1398, the Protect Americas Innovation and Economic Security from CCP Act - provisions related to restoring DOJ's "China Initiative" H.R. 1516, the DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act - provisions related to the definition of "Chinese entities of concern" and DHS funding S. 2714, the CREATE AI Act - provisions related to NSF's AI programs including NAIRR S. 1956, the Invent Here, Make Here Act - provisions related to manufacturing and commercialization of federally funded research; tech transfer S. 2220, the PREVAIL Act - provisions related to reforms to the PTAB framework H.R. 8333, the BIOSECURE Act - provisions related to prohibitions on certain biotech suppliers S. 4394, the NSF AI Education Act - provisions related to scholarship and fellowship programs in AI at NSF H.R. 6213, the National Quantum Initiative Reauthorization Act - provisions relate to quantum science programs at NSF, DOE, and NASA General issues related to the importance of robust funding for NSF, DOD, NASA, and DOE Office of Science General issues related to research partnerships with the Army Futures Command and the Pathfinder program General issues related to the outlook for NASA reauthorization and budget, including provisions related to Science, Space Technology, and STEM Education General issues related to research security and NSPM-33 General issues related to F&A cost reimbursements General issues related to AI legislation related to science and innovation; and proposals impacting NSF and DOE

Client expense: $40,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2024 S. 2115: Medical Supply Chain Resiliency Act S. 3558: Prohibiting Foreign Access to American Genetic Information Act of 2024 Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Client expense: $6,880,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $62,254 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023 S. 4713 - The IDEA Act (Inventor Diversity for Economic Advancement Act) S. 4840/ H.R. 9221 - Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Counterfeiting H.R. 8684, S. 2934, SHOP Safe Act March-In Rights S. 1956, Invent Here, Make Here Act

Client expense: $1,410,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Patent & Trademark Office (PTO), SENATE

H.R. 8070, Servicemember Quality of Life Improvement and National Defense Authorization Act for Fiscal Year 2025 - issues related to telecommunications service and equipment; S. 4638, National Defense Authorization Act for Fiscal Year 2025 - issues related to telecommunications service and equipment; S. 4795, Report 118-198, Departments of Commerce and Justice, Science, and Related Agencies Appropriations Bill, 2025; S. 3781, Institute for Telecommunication Sciences Codification Act; H.R. 1353, Advanced, Local Emergency Response Telecommunications Parity Act; S. 4569, TAKE IT DOWN Act; S. 275, Rural Broadband Protection Act of 2024; S. 690, Network Equipment Transparency Act (NET Act); S.1008, Setting Consumer Standards for Lithium-Ion Batteries Act; S. 1956, Invent Here, Make Here Act of 2024; S. 2238, PLAN for Broadband Act; S. 2714, CREATE AI Act of 2023; S. 3162, TEST AI Act of 2023; S. 3312, Artificial Intelligence Research, Innovation, and Accountability Act of 2023; S. 3606, National Earthquake Hazards Reduction Program Reauthorization Act of 2024; S. 3849, Promoting United States Leadership in Standards Act of 2024; S. 3943, Accelerating Networking, Cyberinfrastructure, and Hardware for Oceanic Research (ANCHOR) Act; S. 4178, Future of Artificial Intelligence Innovation Act of 2024; S. 4394, NSF AI Education Act of 2024; S. 4487, Small Business Artificial Intelligence Training Act of 2024; S. 4596, Artificial Intelligence Public Awareness and Education Campaign Act; S. 4769, Validation and Evaluation for Trustworthy (VET) Artificial Intelligence Act

Client expense: Not reported · Firm income: $60,000

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act) S. 4840/H.R. 9221 (RESTORE Patent Rights Act) Comments to USPTO on Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting (Docket No. PTO- P-2024-0003) S. 4875 (Nurture Originals, Foster Art, and Keep Entertainment Safe (NO FAKES) Act) S. 2780 (Medication Affordability and Patent Integrity Act)

Client expense: Not reported · Firm income: $53,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

General provisions related to science and engineering research at NSF, DOE, DOD, NASA, NIH, and IES in FY 2025 H.R. 9026 /S. xxxx, the FY 2025 Commerce-Justice-Science Appropriations bill - provisions related to funding for NSF and NASA (including Science, Space Technology, STEM Education, and lunar gravitational waves) H.R. 8774 /S. xxxx, the FY 2025 Defense Appropriations bill - provisions related to funding for basic and applied research (6.1-6.3) including Defense-Wide basic research initiatives and funding at DARPA; provisions related to research programs within Army Futures Command; provisions related to dependable AI for national security H.R. 8997 /S. xxxx, the FY 2025 Energy-Water Appropriations bill - provisions related to funding for the Dept. of Energys Office of Science, ARPA-E, and language related to independent review and applied research for cleanup decision-making H.R. xxxx /S. xxxx, the FY 2025 Labor-HHS-Education Appropriations Act - provisions related to funding for the National Institutes of Health, and the Institute of Education Sciences (and National Center for Special Education Research) H.R. 8070/S. xxxx, the FY 2025 National Defense Authorization Act - provisions related to defense S&T basic and applied research (6.1-6.3); research security; research programs within Army Futures Command; dependable AI for national security; potential amendments related to Sec. 117 foreign gift reporting for universities and Workforce Pell Act S. xxxx, the LOANS for Biomedical Research Act - provisions related to loans to encourage tech transfer and start ups in biomedical research H.R. xxxx/S. xxxx, the American Privacy Rights Act - provisions related to inclusion of universities as covered entities; impact on education research S. 1956, the Invent it Here, Make it Here Act - provisions related to manufacturing and commercialization of federally funded research S. 2220, the PREVAIL Act - provisions related to reforms to the PTAB framework H.R. 7085, the BIOSECURE Act - provisions related to prohibitions on certain biotech suppliers S. 4207, the Spectrum and National Security Act - provisions related to funding mechanism for NSF General issues related to the importance of robust funding for NSF, DOD, NASA, and DOE Office of Science General issues related to research partnerships with the Army Futures Command and the Pathfinder program General issues related to the outlook for NASA reauthorization and budget, including provisions related to Science, Space Technology, and STEM Education General issues related to research security and NSPM-33 General issues related to indirect cost reimbursements General issues related to NSF programs including NAIRR and NSF Engines and NSF MREFC infrastructure projects General issues related to AI legislation related to science and innovation; and proposals impacting NSF and DOE General issues related to cybersecurity research and workforce General issues related to research collaborations with ORNL General issues related to the Administrations NIST proposed framework related to march-in rights and the impact on basic research

Client expense: $50,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2023 S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues

Client expense: $6,960,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---S.1956 Invent Here, Make Here Act of 2023 (Baldwin) ---Bayh-Dole Act ---March-In Rights ---Reasonable Pricing Clause ---NIST RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March in Rights Compulsory Licensing Data Privacy Issues ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---H.R. 8818: American Privacy Rights Act of 2024 ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Diversity in Patenting ---S.2566: Inventor Diversity for Economic Advancement (IDEA) Act Drug Patenting ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.113: Prescription Pricing for the People Act of 2023 ---S.142: Preserve Access to Affordable Generics and Biosimilars Act ---S.148: Stop STALLING Act ---S.150: Affordable Prescriptions for Patients Act of 2023 ---S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents ---S. 2780 - Medication Affordability and Patient Integrity Act ---S.3583/H.R.6986: A bill to address patent thickets ---H.R.5475 Prohibiting Adversarial Patents Act of 2023 (Fitzgerald - WI) ---H.R. 6275 Protecting Consumer Access to Generic Drugs Act ---FTC Orange Book Delisting Initiative ---Orange Book Listing ---PTO Proposed Rules on Terminal Disclaimer Practice ---Restrictions on Intellectual Property Rights Foreign Drug Data Protection Law ---H.R.7085: BIOSECURE Act ---H.R.7520: Protecting Americans Data from Foreign Adversaries Act of 2024 ---S.3558: A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Intellectual Property Enforcement ---China ---TRIPS Waiver Patent Reform ---H.R.4575: Prohibiting Adversarial Patents Act (PAPA) ---S.79/H.R.1717: Interagency Patent Coordination and Improvement Act of 2023 ---S.2140: Patent Eligibility Restoration Act (PERA) ---S.2220/H.R.4370: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act ---Patent Litigation Reform Patenting of Biological Inventions ---S.2140: Patent Eligibility Restoration Act (PERA) ---Section 101 Modernization World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge World Trade Organization (WTO) ---13th Ministerial Conference ---TRIPS Waiver

Client expense: $1,790,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), White House Office

H.R. 5475 - Protecting American Patents Act H.R. 3535 - Advancing Americas Interests Act S. 2140 - Patent Eligibility Restoration Act S. 2220/H.R. 4370 - PREVAIL Act H.R. 5874 - Restoring Americas Leadership in Innovation Act NIST Draft Interagency Guidance Framework for Considering the exercise of March-In Rights (Docket No.: 230831-0207) H.R. 2670 - National Defense Authorization Act for Fiscal Year 2024 S. 1956 - Invent Here, Make Here Act of 2023

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); Biosimilar Red Tape Elimination Act (S. 2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; REMEDY Act (S. 1209); FDA Modernization Act 3.0 (H.R. 7248); Increasing Transparency in Generic Drug Applications Act (S. 775); Medication Affordability and Patent Integrity Act (S. 2780); Patent listing; Requirements for generic drug-device combination products; priority review vouchers; 3-year exclusivity; Biosecure Act (H.R. 7085, H.R. 8333, S. 3385); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete); Invent Here, Make Here (S. 1956).

Client expense: Not reported · Firm income: $300,000

CHIPS and Science Act (Public Law 117-167); Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S.1956, Invent Here, Make Here Act of 2023 Issues related to the implementation of the National Semiconductor Technology Center, federal incentives for semiconductor research and development and manufacturing, CHIPS Act funding and implementation, semiconductor security, artificial intelligence, quantum computing, National Quantum Initiative

Client expense: $2,010,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

CHIPS and Science Act (Public Law 117-167) and implementation; Chip Equipment Quality, Usefulness, And Integrity Protection (Chip Equip) Act; S.1956, Invent Here, Make Here Act of 2023 Issues related to Bayh-Dole and domestic manufacturing, federal incentives for semiconductor manufacturing, CHIPS Act funding and implementation, and supply chain resiliency

Client expense: $2,010,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues relating to technological and semiconductor workforce, issues relating to commercialization of federally funded scientific research, S 1956 "Invent Here Make Here Act"

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Counterfeiting H.R. 8684, S. 2934, SHOP Safe Act March-In Rights S. 1956, Invent Here, Make Here Act

Client expense: $1,850,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, White House Office

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $65,052 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CPT: Patent Trial and Appeal Board, including institution of proceedings, Fintiv/NHK and related procedures Patent-eligible subject matter Injunctive relief against patent infringers Standard Essential Royalty Act, to establish a patent licensing royalty rate-setting judicial panel disadvantageous to patent owners and favorable to patent infringers H.R. 3535 (Advancing Americas Interest Act) to disadvantageously change U.S. firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods S. 2321/H.R. 5893 (Commerce-Justice-Science Appropriations, FY24) report language to erect barriers to Sec. 337 USITC remedies to block importation of U.S. patent-infringing goods Proposals to misuse Bayh-Dole Acts march-in against patent ownership rights based on product price Unilateral changes to Dept. of Energy funding agreements requiring headquarters review of any licensing agreement, undermining the Bayh-Dole Act Comments on Initiatives to Ensure the Robustness and Reliability of Patent Rights (Docket No. PTO-P-2022-0025) Request for Comments Regarding Joint USPTO-FDA Collaboration Initiatives (Docket No. PTO-P-2022-0037) Federal position on proposal at World Trade Organization to waive intellectual property protections due under Trade-Related Aspects of Intellectual Property Rights Agreement with regard to COVID-19-related inventions Comments on U.S. International Trade Commission Investigation No. 332-596, COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities Comments on advance notice of proposed rulemaking, Changes Under Consideration to Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings Before the Patent Trial and Appeal Board (Docket No. PTO-P-2020-0022) S. 2220/H.R. 4370 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) Comments related to National Institutes of Health, Workshop on Transforming Discoveries into Products: Maximizing NIHs Levers to Catalyze Technology Transfer S. 2140 (Patent Eligibility Restoration Act (PERA)) Mandatory customer stay that deprives patent owners of the ability to enforce their patent rights against all parties such as through injunctive relief and that would unfairly protect direct and contributory patent infringers, including large retail corporations Defending American Patents Act, which would punish U.S. patent owners with the loss of six years of patent protection for asserting their patent in a foreign court against an American patent infringer H.R. 5475 (Preventing Adversarial Patents Act), which would radically change from the hallmark of merit-based U.S. patent issuance, by adding denial or unenforceability of patents based on certain characteristics of the patentee Comments on U.S. Patent & Trademark Office, Joint Collaboration Initiative Regarding Standards (Docket No. PTO-C-2023-0034) Digital copyright piracy, site-blocking injunction National Institute of Standards and Technology, Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No. NIST-2023-0008) Comments to U.S. Patent & Trademark Office, regarding WIPO IGC Negotiations on Genetic Resources and Associated Traditional Knowledge (Docket No.: PTO-C-2023-0019) H.R. 7476 (Countering Communist China Act) intellectual property provisions H.R. 8134 (Restoring Americas Leadership in Innovation Act) Comments to USPTO on Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-0004) Comments to USPTO on Patent Trial and Appeal Board Rules of Practice for Briefing Discretionary Denial Issues, and Rules for 325(d) Considerations, Instituting Parallel and Serial Petitions, and Termination Due to Settlement Agreement (Docket No. PTO- P-2023-0048) Leadership in Critical and Emerging Technologies (CET) Act to expedite CET patent examination S. 1956 (Invent Here, Make Here Act)

Client expense: Not reported · Firm income: $19,000

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. International Trade Commission (ITC)

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __ - Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 S. 1241 - Domenic and Eds Law

Client expense: $75,967 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) H.R. ___ Improving Efficiency to Increase Competition Act (IEICA) H.R.5475 - Prohibiting Adversarial Patents Act of 2023 (PAPA) S. ____ - Inventor Diversity for Economic Advancement (IDEA) Act S. 2220 - Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act S. __2140__ Patent Eligibility Reform Act S.1956 - Invent Here, Make Here Act of 2023 S.2140 - Patent Eligibility Restoration Act of 2023 -- regarding policy issues affecting higher education institutions and their faculty and students

Client expense: $74,678 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE